ANI Pharmaceuticals (NASDAQ: ANIP) saw its stock soar 5.29% in pre-market trading on Friday, following the release of its impressive third-quarter results and an upward revision of its full-year 2025 guidance.

The specialty pharmaceutical company reported adjusted earnings per share of $2.04 for Q3, significantly beating the analyst consensus estimate of $1.75. Revenue for the quarter came in at $227.8 million, surpassing expectations of $211 million and representing a robust 53.6% year-over-year increase.

Key drivers of ANI's strong performance included:

• Exceptional growth in the Rare Disease segment, with Cortrophin Gel net revenues surging 93.8% compared to the previous year
• A 20.6% increase in Generics net revenues, boosted by a successful partnered generic launch
• Overall expansion across multiple product lines and specialties

In light of these strong results, ANI Pharmaceuticals raised its guidance for the full year 2025. The company now expects total net revenue to be in the range of $854 million to $873 million, up from its previous forecast. Additionally, ANI projects adjusted earnings per share for 2025 to be between $7.37 and $7.64, exceeding the current FactSet estimate of $7.32.

Nikhil Lalwani, President and CEO of ANI, commented on the results, stating, "ANI had another strong quarter in which we delivered record revenue and adjusted EBITDA, underscoring the strength of our diversified business model and our ability to execute across all three of our business segments."

The market's positive reaction to ANI's results reflects investor confidence in the company's growth trajectory and improved financial outlook for the remainder of 2025.